Coherus Oncology
CHRS
128 hedge funds and large institutions have $81.1M invested in Coherus Oncology in 2025 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 38 increasing their positions, 33 reducing their positions, and 8 closing their positions.
862% more call options, than puts
Call options by funds: $558K | Put options by funds: $58K
225% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 8
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
99% more capital inflows, than outflows
Capital inflows: $15.8M | Capital outflows: $7.94M
15% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 33
12% more funds holding
Funds holding: 114 → 128 (+14)
4.56% more ownership
Funds ownership: 42.7% → 47.26% (+4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$962K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$696K |
| 3 |
Two Sigma Investments
New York
|
+$682K |
| 4 |
Jane Street
New York
|
+$573K |
| 5 |
Two Sigma Advisers
New York
|
+$430K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.46M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$1.48M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$483K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$481K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$426K |
CHRS Hedge Fund Activity: Q4 2025 in Review
128 of the 8,287 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2025, worth a combined $81.1M — down 4.2% from $84.6M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CHRS positions and 8 closed out — a net gain of 18 holders — while 38 added to existing stakes and 33 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $962K. The largest seller was Tang Capital Management, cutting an estimated $3.46M.
- 128 institutional investors held Coherus Oncology (CHRS) as of Q4 2025, up from 114 in Q3 2025.
- Funds reported $81.1M of Coherus Oncology stock for Q4 2025, down 4.2% quarter-over-quarter.
- 26 funds opened new Coherus Oncology positions in Q4 2025 and 8 closed out, a net change of +18 holders.
- The largest Coherus Oncology buyer in Q4 2025 was Millennium Management, an estimated $962K added.
- The largest Coherus Oncology seller in Q4 2025 was Tang Capital Management, an estimated $3.46M sold.
Based on aggregated 13F filings for Q4 2025.